6620 Stock Overview
A specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Handa Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$73.70 |
| 52 Week High | NT$196.00 |
| 52 Week Low | NT$49.90 |
| Beta | 1.28 |
| 1 Month Change | 34.98% |
| 3 Month Change | 7.28% |
| 1 Year Change | -59.84% |
| 3 Year Change | 6.50% |
| 5 Year Change | 148.90% |
| Change since IPO | -21.60% |
Recent News & Updates
Shareholder Returns
| 6620 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 35.2% | 4.6% | 1.3% |
| 1Y | -59.8% | 1.2% | 27.5% |
Return vs Industry: 6620 underperformed the TW Pharmaceuticals industry which returned 1.2% over the past year.
Return vs Market: 6620 underperformed the TW Market which returned 27.5% over the past year.
Price Volatility
| 6620 volatility | |
|---|---|
| 6620 Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 3.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.7% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6620's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6620's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Toshiyo Chen | www.handapharma.com.tw |
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company provides Quetiapine XR for the treatment of Schizophrenia; and Dexlansoprazole DR capsules. It also develops ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; 505(b)(2)NDA, a therapeutic product; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-027, an oncology products.
Handa Pharmaceuticals, Inc. Fundamentals Summary
| 6620 fundamental statistics | |
|---|---|
| Market cap | NT$10.41b |
| Earnings (TTM) | NT$452.32m |
| Revenue (TTM) | NT$972.97m |
23.0x
P/E Ratio10.7x
P/S RatioIs 6620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6620 income statement (TTM) | |
|---|---|
| Revenue | NT$972.97m |
| Cost of Revenue | NT$1.29m |
| Gross Profit | NT$971.68m |
| Other Expenses | NT$519.36m |
| Earnings | NT$452.32m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.20 |
| Gross Margin | 99.87% |
| Net Profit Margin | 46.49% |
| Debt/Equity Ratio | 0% |
How did 6620 perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield31%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 20:15 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Handa Pharmaceuticals, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | KGI Securities Co. Ltd. |
| Hsuan Chen | KGI Securities Co. Ltd. |